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Diuretics
Are Our Ideas Based on Knowledge?*
Stephen S. Gottlieb, MD
Baltimore, Maryland
“The extent of our knowledge comes not only short of the
reality of things, but even of the extent of our own ideas.”
—John Locke,
An Essay Concerning Human Understanding (1)
Although there is no doubt that diuretics are involved in the
progression of heart failure, it is controversial whether they
are detrimental or beneficial. Are they the culprit of mor-
tality and morbidity or the means of preventing adverse
consequences? Are these agents remnants of treatment from
unenlightened times or the epitome of treatment that
improves symptoms and outcomes? Fortunately, studies are
now starting to address these important questions.
There is no question that diuretics improve symptoms.
Despite the lack of good outcome studies, guidelines rec-
ognize the need for diuretics in order to improve symptoms
and quality of life. Recently, however, they have been seen
as necessary evils whose use should be minimized as much as
possible.
See page 2233
Suggestions that diuretics may be detrimental derive from
the many studies that consistently demonstrate that patients
receiving higher doses have worse outcomes (2). The
hypothesis that diuretics (especially furosemide) cause
deterioration is reasonable, as they cause neurohormonal
activation, which, in turn, could exacerbate heart failure.
Furthermore, diuretics can worsen renal function, and,
with worsening renal function being prognostic, the
connection between diuretics and outcomes seems logi-
cal. With publication of a study showing that furosemide
increases cardiac dilatation in an animal model of heart
failure, the conclusion that the use of diuretics should be
minimized was obvious (3).
But the story is not that simple. Each step above has
limitations that are only now being discussed. Yes, higher
doses of diuretics are clearly associated with worse out-
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expected to have worse outcomes.
It also turns out that diuretics sometimes improve renal
function. Renal perfusion might actually increase when
central venous pressure decreases, a fact recognized more
than a century ago (4). Recently, intra-abdominal pressure
was shown to be associated with glomerular filtration rate,
and the extent of reduction with diuresis was associated with
improvement in renal function (5). It is possible that
elevated right-sided pressures are associated with increased
renal parenchymal pressure, which might decrease renal
perfusion. Decreased renal perfusion secondary to increased
renal afterload may also be the cause of impaired GFR in
some fluid-overloaded patients. The importance of volume
is supported by the association of right atrial pressure, but
not cardiac index, with serum creatinine in the ESCAPE
(Evaluation Study of Congestive Heart Failure and Pulmo-
nary Artery Catheterization Effectiveness) trial (6).
It is also not clear that declining renal function caused by
diuresis engenders poorer outcomes. Clinicians often limit
diuresis because of worsening renal function, but a recent
study suggests that hemoconcentration is associated with
improved outcome, even though it is also associated with
increased serum creatinine (7). Similarly, DOSE (Diuretic
Optimization Strategies Evaluation) (8) showed more di-
uresis and higher serum creatinine with higher diuretic
doses, but no evidence that this had adverse consequences.
Even the neurohormonal activation associated with di-
uresis needs to be reconsidered in the age of neurohormonal
blockade. Although the renin-angiotensin system is stimu-
lated by volume contraction and stimulation of barorecep-
tors and the macula densa (9), the importance of these
actions when angiotensin-converting enzyme inhibitors are
used is unknown. Similarly, the adrenergic stimulation
caused by heart failure is decreased by beta-adrenergic
blockers. Furosemide may even have beneficial neurohor-
monal effects, decreasing sympathetic nervous system activ-
ity and stimulating renal production of prostaglandin E2 (10).
And now Damman et al. (11) in this issue of the Journal
rovide provocative data suggesting that furosemide can
revent renal injury. Both urinary kidney injury molecule
KIM)-1 and urinary N-acetyl-beta-D-glucosaminidase
NAG) concentrations increased significantly after diuretic
ithdrawal and decreased with reinstitution of furosemide.
igh concentrations of these markers are potentially mean-
ngful, as KIM-1 is up-regulated in proximal tubule cells
fter nephrotoxic or ischemic injury, NAG is released into
he urine after renal proximal tubule injury, and both
iomarkers are highly prognostic (12). Such findings sug-
est that fluid overload could be detrimental to the kidney
r that furosemide is somehow protective.
Of course, however, this investigation does not answer
he question regarding whether diuretics are beneficial or
armful to outcomes. The study is small, and the inconsis-
ency of the findings is worrisome. If furosemide is protec-
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associated lipocalin (NGAL) to be elevated in the serum
and urine after furosemide’s withdrawal; NGAL is up-
regulated after renal tubular injury (and may participate in
limiting kidney damage) (13), and both urinary and serum
NGAL are early markers of acute kidney injury, with
prognostic importance (14). Surprisingly, serum and urinary
NGAL were not significantly affected by the interventions
of this study. The atrial natriuretic peptide data are also
inconsistent, with atrial natriuretic peptide remaining ele-
vated even after the reinstitution of furosemide.
The implications of the study by Damman et al. (11) are
dependent on understanding the physiology of the renal
biomarkers tested, but much remains to learn about these
substances. There are differences in the time course and
sensitivity of different biomarkers (15), and factors other
than renal injury can impact their concentrations. With our
present state of knowledge, we cannot make firm conclu-
sions from the present study. Nevertheless, the study em-
phasizes that our ideas about diuretics are not equivalent to
their reality. Only increasing knowledge will permit us to
better use these commonly prescribed, and frequently dis-
paraged, agents.
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